Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating or preventing obesity and metabolic syndrome

A technology for metabolic syndrome and composition, applied in the field of medicine, can solve the problems of obesity patients prone to diabetes and other problems, and achieve the effects of reducing the risk probability of liver damage, effectively controlling indicators, and improving compliance.

Inactive Publication Date: 2012-12-05
LUNAN PHARMA GROUP CORPORATION
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Obese patients are prone to diabetes, and currently there is no drug on the market specifically for the treatment of obesity and the prevention of diabetic complications, and taking orlistat alone will bring certain side effects such as steatorrhea or fat-soluble vitamin deficiency, the United States The Food and Drug Administration (FDA) warned in May 2010 of the risk of serious liver damage from orlistat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating or preventing obesity and metabolic syndrome
  • Pharmaceutical composition for treating or preventing obesity and metabolic syndrome
  • Pharmaceutical composition for treating or preventing obesity and metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Preparation of compound tablets

[0022]

[0023] Preparation process: Weigh the prescribed amount of orlistat, miglitol, starch, and microcrystalline cellulose and mix them evenly. In addition, add an appropriate amount of 15% starch slurry to the mixed powder, mix evenly, make soft material, pass through an 18-mesh nylon sieve to make wet granules, dry at about 60℃, and control the moisture of the dry granules below 1.5%. The 20-mesh sieve is sized, then mixed with magnesium stearate, and compressed into tablets.

Embodiment 2

[0024] Example 2 Preparation of compound tablets

[0025]

[0026] Preparation process: The preparation method is the same as in Example 1 except that the auxiliary materials are different.

Embodiment 3

[0028]

[0029] Preparation process: orlistat is passed through a 100 mesh sieve, hydroxypropyl cellulose-4M and microcrystalline cellulose are passed through an 80 mesh sieve, and the prescription amount of orlistat, hydroxypropyl cellulose-4M, and microcrystalline fiber are weighed. Mix the ingredients evenly, add 8% PVP anhydrous ethanol solution for granulation, dry at 60°C, and sieve the dry granules with a 16-mesh sieve. Add the prescribed amount of magnesium stearate to the dry granules.

[0030]

[0031] Preparation process: Miglitol goes through a 100-mesh sieve, sodium carboxymethyl cellulose and lactose through an 80-mesh sieve, weigh the prescription amount of Miglitol, sodium carboxymethyl cellulose and lactose and mix them evenly, add 6% PVP Granulate with 95% ethanol solution in an appropriate amount, dry at 60°C, and sieve the dry granules with a 16-mesh sieve. Add the prescribed amount of magnesium stearate to the dry granules.

[0032] c. Double-layer tablets are ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses pharmaceutical composition for treating or preventing obesity and metabolic syndrome and belongs to the field of pharmaceuticals. The pharmaceutical composition comprises active ingredients, namely orlistat and miglitol according to a preferable weight ratio of 1:0.1-100, and a more preferable weight ratio of 1:0.5-10. The pharmaceutical composition can be made into conventional pharmaceutical dosage forms, preferably the solid form. The pharmaceutical composition has evident synergistic effect on treating or preventing obesity and metabolic syndrome, is capable of lowering the risks of cardiovascular diseases and has broad medical application prospect.

Description

Technical field [0001] The invention belongs to the field of medicine, and relates to a pharmaceutical composition for treating or preventing obesity, in particular to a pharmaceutical composition using miglitol and orlistat as active pharmaceutical ingredients and its use for treating or preventing obesity and Medicinal uses of metabolic syndrome. Background technique [0002] With the development of economy, the improvement of material living conditions and the unreasonable dietary structure, obesity is spreading like a plague in developed countries and developing countries with rapid economic development. The incidence rate is increasing year by year, and it is becoming younger. There are more than 70 million obese patients in my country (excluding childhood obesity), accounting for 5.4% of the total population. In large cities such as Beijing and Shanghai, nearly one-third of adults are overweight, making them a high-risk area for obesity. In the past ten years, the detecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/445A61K31/365A61P3/04A61P3/00
Inventor 赵志全赵涛左超
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com